Antisense Therapeutics (ASX:ANP) Trading 16% Higher

Antisense Therapeutics Limited (ASX:ANP)’s stock price traded up 16% on Monday . The company traded as high as A$0.06 ($0.04) and last traded at A$0.06 ($0.04), 2,983,445 shares changed hands during mid-day trading. The stock had previously closed at A$0.05 ($0.04).

The firm’s 50-day moving average is A$0.05. The stock has a market capitalization of $22.69 million and a price-to-earnings ratio of -5.70.

Antisense Therapeutics Company Profile (ASX:ANP)

Antisense Therapeutics Limited, a biopharmaceutical drug discovery and development company, engages in the research and development of antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 that has completed Phase IIa for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of CD49d for the treatment of inflammation associated with duchenne muscular dystrophy.

Featured Story: Intrinsic Value

Receive News & Ratings for Antisense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antisense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply